Menu
Search Close

News

Scancell Raises £1.0 Million In Rights Issue

15th June 2005

Oxford, UK, 15 June 2005 - Scancell Limited announces the completion of its Rights Issue funding of £1.0m. The round was well supported by Scancell’s existing shareholders who include, Bioscience VCT, Oxford Capital Partners and the Oxford Technology VCTs.

Scancell will use the funds to advance its development programmes as it advances towards the clinic. Based in Biocity, Nottingham, UK, Scancell is one of the leading drug discovery companies focused on cancer therapeutics through the development of its antibody technology. Scancell was founded in 1997 as a spin out of the University of Nottingham by Professor Lindy Durrant.

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The Company has four therapeutic antibodies in development and a pipeline of improved cancer vaccines based upon its proprietary ImmunoBody® technology. Scancell has already secured major technology-validating collaborations with significant players in the sector including Celltech, Genmab and ISU.

Mike Capaldi, CEO of Scancell, said: “We are pleased to have received strong support from our shareholders. Despite the challenging environment for biotech funding, Scancell has successfully closed this round and is in discussions with a number of commercial partners.”

David Mott, Partner at Oxford Capital Partners, said: “Scancell have made strong scientific progress over the past 18 months and we are confident that the technology will deliver. The new funds will enable Scancell to reach several critical value milestones.”

Webcasts, Interviews and Media Coverage

Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies

Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer

Tue, 30 Oct 2018 14:05:00

Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma

Wed, 24 Oct 2018 05:40:00

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

Tue, 25 Sep 2018 06:20:00